Skip to content
DataLookout
Menu

NCT07365462

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 35 → 48 locations
  2. Notable Eligibility criteria expanded, about 9 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial sites expanded: 18 → 35 locations
  3. Minor Study sites: 17 to 18v4
  4. Minor Trial sites expanded: 6 → 17 locations
    • Start date: Jan 23, 2026 to Feb 6, 2026
    v3
  5. Notable Recruitment opened
    • Trial sites expanded: 0 → 6 locations
    • Start date changed from estimate of Jan 2026 to Jan 23, 2026
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 8 Based on the Blinded Central AIMS Video Raters' Assessment
Timeframe: Baseline and Week 8

Secondary (1)

Percentage of Participants Who Are a Clinical Global Impression - Improvement (CGI-I) Responder 1 at Week 8

Arms and interventions

NBI-1065890Experimental

Participants will receive NBI-1065890.

PlaceboPlacebo comparator

Participants will receive placebo matching NBI-1065890.

Drugs: NBI-1065890, Placebo

Sites

48 sites in 6 countries

United States 31, Bulgaria 9, Slovakia 3, Czechia 2, Romania 2, Puerto Rico 1